Santhera price target raised to CHF 30 from CHF 25 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and keeps a Buy rating on the shares. Santhera remains engaged in various national processes of health technology assessments, pricing negotiations, and reimbursement decisions, the analyst tells investors in a research note. The firm believes vamorolone’s commercial traction continues.